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Venous thromboembolism is a frequent complication in patients with cancer. Homozygous carriers of 
the fibrinogen gamma gene (FGG) rs2066865 have a moderately increased risk of venous 
thromboembolism, but the effect of the FGG variant in cancer is unknown. We aimed to investigate 
the effect of the FGG variant and active cancer on the risk of venous thromboembolism. Cases with 
incident venous thromboembolism (n= 640) and a randomly selected age-weighted sub-cohort 
(n=3734) were derived from a population-based cohort (the Tromsø study). Cox-regression was used 
to estimate hazard ratios with 95% confidence intervals for VTE according to categories of cancer and 
FGG. In those without cancer, homozygosity at the FGG variant was associated with a 70% (HR 1.7 95% 
CI 1.2-2.3) increased risk of venous thromboembolism compared to non-carriers. Cancer patients 
homozygous for the FGG variant had a 2-fold (HR 2.0 95% CI 1.1-3.6) higher risk of venous 
thromboembolism than cancer patients without the variant. Moreover, the 6-month cumulative 
incidence of venous thromboembolism among cancer patients was 6.4% (95% CI, 3.5%-11.6%) in 
homozygous carriers of FGG and 3.1% (95% CI, 2.3%-4.7%) in those without risk alleles. A synergistic 
effect was observed between rs2066865 and active cancer on the risk of VTE (Synergy index: 1.81, 95% 
CI: 1.02-3.21, Attributable proportion: 0.43, 95% CI: 0.11-0.74). In conclusion, homozygosity at the FGG 






Venous thromboembolism (VTE), a collective term for deep vein thrombosis (DVT) and pulmonary 
embolism (PE), is a common disease associated with substantial short- and long-term morbidity and 
mortality 1, 2. The incidence of VTE is 1-2 per 1000 person-years, and it increases steeply with age 3. 
Malignant disease is associated with a four- to seven-fold increased risk of VTE, and 20-25% of all first 
lifetime VTE-events are cancer-related 4, 5. VTE, particularly in cancer, leads to prolonged and more 
frequent hospitalizations, and has a substantial impact on quality of life 6, 7. Complications of a VTE, 
such as recurrence, post-thrombotic syndrome and treatment-related bleeding, occur more frequently 
in cancer patients 6, 8, 9, and the risk of death is higher in cancer patients with than without VTE 10, 11.  
Family and twin studies suggest that VTE is highly heritable, and likely results from an interplay 
between inherited and environmental factors 12, 13. Fibrinogen, the precursor of fibrin, is an essential 
component in the final stage of the coagulation cascade. The fibrinogen molecule has three subunits 
called Aα, Bβ and γ, which occur in pairs for a total number of six subunits. The γ chain, transcribed 
from the fibrinogen gamma gene (FGG) located on chromosome 4, has two isoforms, γA and γ’. In the 
Leiden Thrombophilia Study, the fibrinogen gamma gene (FGG) rs2066865 single nucleotide 
polymorphism (SNP) was first proposed as a risk factor for VTE by reducing fibrinogen γ’ levels 14. 
Several later genotyping 15, 16 and genome-wide association studies (GWAS) 17, 18 confirmed an 
association between rs2066865 and VTE risk, whereas two cohort studies found no significant 
association 19, 20. In a recent meta-analysis including seven studies, rs2066865 was associated with an 
increased risk of VTE (OR 1.61, 95% CI 1.34-1.93) 21.  
The majority of the genetic studies have excluded individuals with cancer-related thrombosis. 
However, as prothrombotic genotypes are fixed, and not influenced by disease, interventions and 
complications, they may be attractive candidates as biomarkers of VTE risk in cancer patients. Recent 
studies have suggested that interactions between cancer and other prothrombotic genotypes (FV 




To the best of our knowledge, no study has investigated the impact of rs2066865 on the risk of VTE in 
cancer patients. Therefore, we aimed to investigate the joint effect of rs2066865 and active cancer on 




The Tromsø Study is a single-center population-based cohort, following residents of the municipality 
of Tromsø, Norway, with repeated health surveys. The case-cohort was derived from the fourth survey 
(Tromsø 4), which included 27 158 participants aged 25-97 years. A detailed cohort profile of the 
Tromsø study has been published previously 26. The study was approved by the Regional Committee 
for Medical and Health Research Ethics in Northern Norway, and all participants provided informed 
written consent to participation. From enrolment in Tromsø 4 (1994/95), subjects were followed until 
December 31, 2012. Detailed information regarding identification and validation of VTE-events are 
described in the method supplementary of appendix. 
In total, 710 participants developed VTE during follow-up. Of these, 26 did not have blood 
samples available or of sufficient quality for DNA analyses. The remaining 684 subjects were included 
as the cases in our study. A subcohort (n=3 931) was composed by randomly sampling individuals from 
Tromsø 4 weighted for the age distribution of the cases in 5-year age-groups. Due to the nature of the 
case-cohort design, where each participant has the same probability of sampling, 72 of the cases were 
also in the subcohort. Subjects with a history of cancer prior to inclusion (n=232) and subjects with 
missing information on rs2066865 (n=9) were excluded from the analysis. The final case-cohort 
consisted of 4 374 subjects, with 640 cases and 3 734 in the subcohort. A flow chart of the case-cohort 





Baseline measurements and genotyping 
Baseline measurements and genotyping methods are described in the Online supplementary methods. 
 
Cancer exposure 
Cancer assessment is described in the Online supplementary methods. Previous studies have shown a 
strong temporal relation between cancer diagnosis and incident VTE, and up to 50 % of cancer-related 
VTE events presents within a 2.5 year interval (from 6 months preceding the cancer diagnosis until 2 
years following the cancer diagnosis) 27, 28. Therefore, a VTE was defined as related to active cancer if 
it occurred within this time period.  
Subjects who survived the active cancer period without a VTE were censored at the end of the 
active cancer period (i.e. 2 years after cancer was diagnosed). The censoring was performed because 
information regarding remission and relapse of cancer was unavailable, and extension of the 
observation period of cancer could result in dilution of the estimates due to inclusion of VTEs not 
necessarily caused by cancer. This approach resulted in censoring of 14 VTE cases that occurred after 
the active cancer period. Thus, 626 VTE cases were included in the final analyses. 
 
Statistical Analysis 
Statistical analyses were performed using STATA version 15.0 (Stata Corporation LP, College Station, 
TX, USA). Cox proportional hazards regression models were used to obtain age- and sex- adjusted 
hazard ratios (HR) with 95% confidence intervals (CIs) for VTE across categories of cancer status (no 
cancer/active cancer) and FGG risk alleles. Cancer was assessed as a time-dependent covariate in the 
model. Subjects who developed cancer contributed person-time as unexposed from the inclusion 
date until six months prior a cancer diagnosis, and thereafter contributed person-time in the active 
cancer group as exposed. Absolute incidence rates (IR) were calculated based on person-time from 




alleles, subjects with no cancer and no risk alleles were used as the reference group in the Cox 
model. Based on the total active cancer person-time at risk derived from the source cohort, 1-
Kaplan-Meier curves were used to estimate the cumulative incidence of VTE in subjects with active 
cancer according to the presence of FGG risk alleles. Methods for assessing synergism between FGG 





The mean follow-up of the case-cohort was 12.6 years. In total, 854 subjects had active cancer, of 
which 167 experienced an incident VTE. The baseline characteristics of the entire case-cohort and in 
those with active cancer during follow-up are presented in Table 1. Subjects who developed active 
cancer were slightly older (61 ± 10 years vs. 58 ± 13 years) and reported a higher frequency of daily 
smoking (46% vs. 35%) compared to the entire case-cohort. The minor allele frequency of rs2066865 
was 0.26, which is comparable to reference populations 14, 29. The homozygous variant of the FGG 
was present in 289 (6.6%) subjects, the heterozygous variant in 1 723 (39.4%) subjects, while 2 362 
(54.0%) subjects were non-carriers of the FGG variant. The allele frequency was essentially similar in 
subjects who developed cancer.  Expected versus observed proportions of hetero- and homozygous 
individuals in the subcohort according to the Hardy-Weinberg equilibrium are presented in 
Supplementary table 1.  
The clinical characteristics of the VTE events stratified by the presence of active cancer are 
shown in table 2. Compared to the non-cancer-related VTEs, cancer-related VTEs were more often a 
DVT (59.2% vs. 55.5%) than a PE (40.7% vs. 44.4%). The prevalence of provoking factors such as acute 
medical conditions, immobilization and surgery were essentially similar between the two groups, as 
were the total proportion of VTEs with one or more concurrent provoking factors (44.3% vs. 44.7%). 
Non-cancer related VTEs were more likely to be associated with traumas (9.6% vs. 2.4%) while other 
provoking factors (i.e. venous catheters) were more frequent in cancer-related VTE (8.4% vs. 3.7%).  
In participants without cancer, the IR of VTE increased from 1.2 (95% CI 1.1-1.4) per 1000 
person-years among non-carriers of FGG rs2066865 to 2.0 (95% CI 1.5-2.7) per 1000 person-years 
among those with two risk alleles. Accordingly, the risk of VTE was 70% (HR 1.7, 95% CI 1.2-2.3) higher 
in those with two risk alleles at FGG compared to non-carriers (Table 3). In subjects with active cancer, 
the risk was 12-fold higher (HR 11.9, 95% CI 9.3-15.2) in those with no FGG risk alleles, and 22-fold 




without risk alleles. Cancer patients with two risk alleles at FGG had a 2-fold higher (HR 2.0, 95% CI 1.1-
3.6) risk of VTE compared to cancer patients without risk alleles. In sub-analyses, the effect of active 
cancer and homozygosity at FGG yielded higher risk estimates for PE (HR 2.9, 95% CI 1.3-6.6) than for 
DVT (HR 1.6, 95% CI 0.7-3.5).  
The cumulative incidence of VTE during the active cancer period is shown in Figure 2. The 
cumulative incidence of VTE increased particularly during the first six months following a cancer 
diagnosis, where we found a substantially steeper incline in the incidence curve for subjects with two 
risk alleles at FGG rs2066865. The cumulative incidence of VTE among homozygous carriers was 5.0% 
(95% CI, 2.4%- 9.6%), 6.4% (95% CI, 3.5%-11.6%), and 8.0% (95% CI, 4.6%-13.9%) at 3 months, 6 
months and 24 months after cancer diagnosis, respectively. The corresponding figures for cancer 
patients who were non-carriers were 2.1% (95% CI, 1.5%-3.0%), 3.1% (95% CI, 2.3%-4.7%), and 4.8% 
(95% CI, 3.8%-6.2%), respectively.  
A supra-additive effect on the risk of VTE was observed for the combination of homozygosity 
at the FGG variant and active cancer (table 4). The RERI was 9.61 (95% CI -2.38-21.61) and the RSI 
was 1.81 (95% CI 1.02-3.21). The proportion attributable to interaction (AP) was 0.43 (95% CI 0.11-
0.74). In sub-group analysis, the estimates of biological interaction were stronger for PE (RSI = 2.37, 





In the present study, we aimed to investigate the joint effect of the rs2066865 SNP at FGG and active 
cancer on the risk of VTE in a case-cohort recruited from the general population. Homozygosity at 
rs2066865, occurring in 6.6% of the study population, was associated with increased risk of VTE. The 
combination of an rs2066865 homozygous risk genotype and active cancer showed a synergistic effect 
on VTE risk (on an additive scale). The effect was particularly strong for PE. The cumulative incidence 
of VTE increased substantially during the first six months following a cancer diagnosis, especially 
among patients with two risk alleles at FGG rs2066865. Our findings suggest that homozygosity at FGG 
rs2066865 may aid to differentiate patients at high and low risk of cancer-related VTE. 
Several observational studies have reported an association between homozygous genotype of 
rs2066865 and increased risk of VTE in Caucasians 14-16, 21. In a recent meta-analysis including seven 
observational studies, the odds ratio of VTE was 1.61 for homozygosity at rs2066865 21. Accordingly, 
in cancer-free subjects, we found that those with two rs2066865 risk alleles had a 1.7-fold higher VTE 
risk than those with 0 risk alleles. The risk estimates for DVT and PE were essentially similar in cancer-
free subjects.  
Even though the role of prothrombotic genotypes in cancer-related VTE have been scarcely 
studied, previous studies have found that some prothrombotic genotypes (e.g. Factor V Leiden and 
prothrombin G20210A) are associated with increased risk of cancer-related VTE 22, 23, 30, 31. Further, the 
combined effect of cancer and Factor V variants (Factor V Leiden and rs4524) exceeded the sum of the 
individual effects, implicating a biological interaction on VTE risk 22, 24. Accordingly, we found that the 
combination of FGG and active cancer yielded a synergistic effect on VTE risk. 
In cancer patients, the cumulative incidence curve of VTE was substantially steeper in 
individuals homozygous for FGG during the first six months following the cancer diagnosis. According 
to the thrombosis potential model 32, several risk factors need to be present concurrently to exceed 




diagnosis, treatment with surgery and/or chemotherapy is typically initiated, and treatment-related 
complications such as acute infection and immobilization frequently occur. Thus, the accumulation of 
several treatment-related risk factors, which adds to the background risk in patients with cancer and 
risk alleles at FGG, may partly explain the substantial increase in VTE incidence the first half year 
following a cancer diagnosis.  
In contrast to cancer-free subjects, we found that the effect of rs2066865 was stronger for PE 
than for DVT in cancer patients. This suggests that the FGG variant may play a more essential role in 
the pathogenesis of PE than DVT in cancer patients. The underlying mechanism(s) for the latter 
observation is unknown, but may imply that rs2066865 is associated with fragile thrombi, which are 
prone to embolization and manifest clinically as PE rather than DVT in cancer patients.   
The mechanism by which the rs2066865 affects susceptibility to VTE is not fully elucidated. 
However, the current hypothesis is that it acts through a phenotype with altered fibrinogen 
composition and formation. The rs2066865 SNP tags the FGG-H2 haplotype. Previous studies have 
shown that homozygous carriers of the FGG-H2 haplotype had lower levels of γ’ fibrinogen and γ’ 
fibrinogen/total fibrinogen concentration 14 without alterations in the total fibrinogen level 33.  The 
suggested mechanism is that the FGG variant favors formation of the abundant γ-chain isoform (Aγ) 
above the minor γ-chain (γ’) through alternative splicing of the mRNA of the FGG-gene 14, 33. Fibrinogen 
γ’ exhibits an inhibitory activity towards thrombin, due to a high affinity binding site on the γ’ chain for 
thrombin exosite II 34, which inhibits thrombin-mediated activation of FVIII 35, FV 36 and platelets 37. 
Moreover, fibrinogen γ’ has been shown to increase the activated protein C (APC) sensitivity 38. 
However, studies on the association between low plasma levels of fibrinogen γ’ and VTE risk have 
shown somewhat inconsistent results 14, 20  
Current anticoagulant prophylaxis regimens efficiently prevent first VTE in cancer patients, but 
at the expense of a substantial risk of major and life-threatening bleedings 39. Therefore, current 




patients 40, 41. Thus, it is vital to recognize patients that are at high risk of cancer associated VTE, in 
order to identify those who would benefit most from thromboprophylaxis.  Prothrombotic genotypes 
are attractive biomarker candidates, which could be used to distinguish between high and low risk of 
VTE in cancer patients, since they are fixed and not affected by the clinical status or treatment-related 
factors.  In the present study, 6.4% of cancer patients with two risk alleles at FGG rs2066865 developed 
VTE during the first 6 months after cancer diagnosis compared to 3.1% of cancer patients without risk 
alleles. Our findings suggest that FGG may be an attractive gene candidate to pursue in future research 
on prediction models of VTE risk in cancer patients. We and others have previously reported similar 
discriminative power of two variants in the F5 gene (rs6025 and rs4524) 23, 24, and a genetic model 
including 9 SNPs reported promising predictive capacity on VTE risk in breast cancer 42. Recently, a new 
risk prediction model for cancer-related VTE, including clinical characteristics and genetic variants, 
reported a strong predictive capacity with AUC of 0.73 and performed better that the Khorana score 
(AUC 0.58) 43.   
The main strengths of present study are the prospective design, high participation rate and 
long-term follow-up, making it possible to capture a large quantity of both incident cancer- and VTE-
events in the study population. Since all participants live within a single hospital catchment area, the 
probability of missing outcomes is low. Moreover, both incident VTE-events and cancer diagnoses were 
systematically validated and objectively confirmed. The study was limited by the lack of statistical 
power in sub-group analysis (i.e. DVT/PE), illustrated by wide confidence intervals for our risk 
estimates. In addition, we did not have access to information on treatment regimens or medical 
complications among cancer patients. Although there is no reason to believe that the type or intensity 
of treatment would be influenced by the genetic makeup, such data could have provided further 




 In conclusion, we found that homozygosity at rs2066865 was associated with an increased risk 
of VTE, and yielded a synergistic effect on the VTE risk in combination with active cancer, particularly 
on the risk of PE. 
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TABLE 1. Baseline characteristics in the entire case-cohort and in the active cancer group  
 Entire case-cohort Active cancer 
Subjects (n) 4374 854 
Age (years) 58 ± 13 62 ± 10 
Sex (Males) 47.0 (2048) 53.0 (456) 
BMI (kg/m2) 26.0 ± 4 26.0 ± 4 
Daily smoking 34.5 (1464) 43.5 (364) 
WBC count (109/L) 7.1 ± 1.8 7.2 ± 1.8 
Platelet count (109/L) 251 ± 60 250 ± 58 
rs2066865* 0.26 0.26 
      1 risk alleles 1723 334 
      2 risk alleles 289 51 
Values are numbers or percentages with numbers in parenthesis or means ±SD.  
Active cancer: period from six months before a cancer diagnosis until two years after.  






TABLE 2. Characteristics of subjects with cancer-related and non-cancer-related first venous 
thromboembolism (VTE) 
 Cancer-related VTE 
 Yes (167) No (459) 
Age at VTE diagnosis (years) 69 ±11 68±14 
Sex (Males) 44.9 (75) 47.3(217) 
VTE type   
Deep vein thrombosis 59.2 (99) 55.5 (255) 
Proximal upper limb  5.1 (5) 2.0 (5) 
Distal upper limb  1.0 (1) 0 (0) 
Proximal lower limb  62.6 (62) 65.9 (168) 
Distal lower limb   12.1 (12) 28.2 (72) 
        Other localizations 19.1 (19)  3.9 (10) 
Pulmonary embolism 40.7 (68) 44.4 (204) 
Unprovoked event NA 54.9 (252) 
Provoking factors   
Surgery a 12.6 (21) 15.3 (70) 
Trauma a 2.4 (4) 9.6 (44) 
Acute medical condition b 15.0 (25) 14.2 (65) 
Immobilization c 20.4 (34) 20.0 (92) 
Other provoking factor d 8.4 (14) 3.7  (17) 
Total provoked e 44.3 (74) 44.7 (205) 
Values are numbers or percentages with numbers in parenthesis or means ±SD; NA, Not applicable; a 
Within 8 weeks before the VTE-event; b Myocardial infarction, ischemic stroke of major infectious 
disease; c Bedrest>3 days, wheelchair, long haul travel>4 h in the past 14 days; d presence of other 







TABLE 3: Age and sex adjusted hazard ratios for venous thromboembolism (VTE) according to categories of fibrinogen gamma gene (FGG) risk alleles and 
cancer status.  
  VTE  PE  DVT 
 Risk Alleles Events HR (95% CI) HR (95% CI)  Events HR (95% CI) HR (95% CI)  Events HR (95% CI) HR (95% CI) 
 0 242 Ref. -  112 Ref. -  130 Ref. - 
No cancer 1 170 1.0 (0.8-1.2) -  70 0.9 (0.6-1.2) -  100 1.1 (0.8-1.4) - 
 2 47 1.7 (1.2-2.3) -  22 1.7 (1.1-2.7) -  25 1.6 (1.1-2.5) - 
 0 89 11.9 (9.3-15.2) Ref.  32 8.3 (5.6-12.5) Ref.  57 15.3 (11.2-21.1) Ref. 
Active cancer 1 64 12.2 (9.2-16.1) 1.1 (0.8-1.5)  29 10.6 (7.1-16.3) 1.3 (0.8-2.2)  35 13.4 (9.2-19.6) 1.0 (0.6-1.5) 
 2 14 22.2 (12.9-38.1) 2.0 (1.1-3.6)  7 22.8 (10.6-49.1) 2.9 (1.3-6.6)  7 21.6 (10.0-46.4) 1.6 (0.7-3.5) 
Active cancer: period from six months before a cancer diagnosis until two years after; CI: Confidence interval; DVT: Deep vein thrombosis; HR: Hazard ratio; 




TABLE 4. Measures of interaction between the homozygous FGG variant and active cancer on VTE 
risk 
 Rothmans synergy 
index (RSI) 
(95% CI) 
Relative excess risk by 
interaction (RERI) 
(95% CI) 
Proportion due to 
interaction (AP)  
(95% CI) 
FGG rs2066865    
VTE 1.81 (1.02 to 3.21) 9.6 (-2.4 to 21.6) 0.43 (0.11 to 0.74) 
PE 2.37 (1.05 to 5.39) 13.4 (-4.8 to 31.7) 0.56 (0.21 to 0.90) 
DVT 1.46 (0.65 to 3.27) 6.3 (-9.6 to 22.1) 0.30 (-0.24 to 0.83) 
Rothmans synergy index (RSI) >1 indicates a positive interaction or more than additivity; Relative 
excess risk by interaction (RERI) >0 indicates a positive interaction or more than additivity; Proportion 






FIGURE 1. Flow chart for the case-cohort 
FIGURE 2. Cumulative incidence of VTE in the presence of FGG rs2066865 risk alleles during the 
active cancer period 
 
 
